Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Innoviva Inc

INVA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$21.17

▲ +0.67%

Market Cap $1.53B · Vol 159.48K

Key Metrics

P/E Ratio

5.11

FWD: 9.30

Market Cap

$1.53B

Small Cap

Div Yield

N/A

Quarterly dividend

EPS Growth

-32.58%

YoY

RSI (14)

59.48

Momentum

Beta

0.34

vs Market

52W High

$25.02

15.39% below

52W Low

$16.52

28.15% above

Volume

159.48K

Avg 261.55K

P/B

1.27

Price-to-book

ROE

29.09%

Return on equity

Free Float

98.99%

Public shares

Shariah Compliance8 STANDARDS

✗ Innoviva Inc (INVA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INVA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.38%

-1.26%

-5.74%

-12.67%

YTD

+5.90%

+7.14%

+59.17%

+42.18%

Financials & Valuation

TTM · Annual

Total Revenue	$411.33M
Net Income	$271.17M
Revenue Growth (YoY)	+19.25%
Gross Margin	74.80%
Operating Margin	39.81%
Net Profit Margin	65.92%
ROE	29.09%
ROA · ROIC	22.26% · 22.18%

P/E Ratio	5.11
Forward P/E (FY1)	9.30
PEG Ratio	0.01
P/S	4.12
P/B	1.27
P/FCF	9.09
EPS Growth	-32.58%
Outstanding Shares	72.25M

Technical Indicators

50-Day SMA	$21.75
200-Day SMA	$21.80
RSI (14)	59.48
Beta	0.34
52-Week High	$25.02
52-Week Low	$16.52

Volume Today	159.48K
Avg Daily Volume (30D)	261.55K
Relative Volume	0.61x
Volatility (10D)	18.78
Volatility (30D)	23.13
Free Float	98.99%

Analyst Consensus

BUY

Current Price $21.17

Mean Target $35.00

52W Low$16.52 52W High$25.02

Current

Target

$16.52 $25.02

Current Analyst target

+65.33% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SF23V0

ISINUS45781M1018

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.